Capon, D. J.Chamow, S. M.Mordenti, J.Marsters, S. A.Gregory, T.Mitsuya, H.Byrn, R. A.Lucas, C.Wurm, F. M.Groopman, J. E.2007-06-052007-06-052007-06-05198910.1038/337525a0https://infoscience.epfl.ch/handle/20.500.14299/75862536900A newly-constructed antibody-like molecule containing the gp120-binding domain of the receptor for human immunodeficiency virus blocks HIV-1 infection of T cells and monocytes. Its long plasma half-life, other antibody-like properties, and potential to block all HIV isolates, make it a good candidate for therapeutic use.Acquired Immunodeficiency Syndrome/immunology/metabolism/*therapyAdjuvantsImmunologic/*chemical synthesis/metabolism/pharmacokineticsAnimalsAntigensSurface/administration & dosage/chemical synthesis/*immunologyBinding SitesAntibodyBindingCompetitiveCell Adhesion MoleculesCell LineDrug DesignHIV Envelope Protein gp120Half-LifeHumans*Immunoglobulin G/administration & dosage/metabolismMiceRabbitsReceptorsComplement/analysisReceptorsFc/analysisReceptorsHIVReceptorsVirus/administration & dosage/*immunologyRetroviridae Proteins/metabolismtext::journal::journal article::research article